New phase 3 data has shown Sanofi’s diabetes combination therapy, LixiLan (insulin glargine+lixisenatide), met blood sugar targets in two pivotal phase 3 trials as the French company prepares ...

LixiLan combines lixisenatide with Sanofi’s Lantus (insulin glargine) in a single product, although this will likely have competition from a rival combo from Novo Nordisk, combining long-acting ...